Amgen announced the presentation of 10 scientific research abstracts, including the final report of the OSLER-1 study, evaluating the long-term safety and efficacy of Repatha in patients with hypercholesterolemia for up to five years. Additional abstracts to be presented include a sub-analysis of the Repatha cardiovascular outcomes study, investigating the effects of triglycerides on cardiovascular risk in patients with established cardiovascular disease, and an evaluation of the utilization of lipid-lowering therapies in patients at high risk for cardiovascular events in a real-world setting. These analyses will be presented at the upcoming American Heart Association Scientific Sessions 2018 in Chicago, Nov. 10-12, and follow the Company’s recent announcement that Repatha is now available in the U.S. at a 60 percent reduced list price.Despite recent advances in the secondary prevention of cardiovascular events, including heart attack and stroke, many patients with cardiovascular disease do not meet, and may not even be aware of, their recommended low-density lipoprotein cholesterol goals, putting them at increased risk for cardiovascular events,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen. “The data that will be presented at AHA contributes to the growing body of compelling clinical evidence on the role for Repatha among high-risk patients for whom statins and other traditional therapies are not enough. Our recent announcement to make Repatha available at a reduced list price should address concerns over out-of-pocket costs, which have been a barrier to its use and help make sure that every patient who needs Repatha gets it.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.